Sphingosine-1-Phosphate Signaling in Endothelial Disorders

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2016 Apr 27

PMID 27115142

Citations 21

Authors

Teresa Sanchez

Affiliations

Soon will be listed here.

Abstract

Numerous preclinical studies indicate that sustained endothelial activation significantly contributes to tissue edema, perpetuates the inflammatory response, and exacerbates tissue injury ultimately resulting in organ failure. However, no specific therapies aimed at restoring endothelial function are available as yet. Sphingosine-1-phosphate (S1P) is emerging as a potent modulator of endothelial function and endothelial responses to injury. Recent studies indicate that S1PR are attractive targets to treat not only disorders of the arterial endothelium but also microvascular dysfunction caused by ischemic or inflammatory injury. In this article, we will review the current knowledge of the role of S1P and its receptors in endothelial function in health and disease, and we will discuss the therapeutic potential of targeting S1PR not only for disorders of the arterial endothelium but also the microvasculature. The therapeutic targeting of S1PR in the endothelium could help to bridge the gap between biomedical research in vascular biology and clinical practice.

Citing Articles

Molecular profiling of the stroke-induced alterations in the cerebral microvasculature reveals promising therapeutic candidates.

Callegari K, Dash S, Uchida H, Shingai Y, Liu C, Khodarkovskaya A Proc Natl Acad Sci U S A. 2023; 120(16):e2205786120.

PMID: 37058487 PMC: 10120001. DOI: 10.1073/pnas.2205786120.

Sepsis-induced AKI: From pathogenesis to therapeutic approaches.

He F, Wang Y, Chen Y, Huang W, Li Z, Zhang C Front Pharmacol. 2022; 13:981578.

PMID: 36188562 PMC: 9522319. DOI: 10.3389/fphar.2022.981578.

Unlocking the Untapped Potential of Endothelial Kinase and Phosphatase Involvement in Sepsis for Drug Treatment Design.

Luxen M, van Meurs M, Molema G Front Immunol. 2022; 13:867625.

PMID: 35634305 PMC: 9136877. DOI: 10.3389/fimmu.2022.867625.

Renal microvascular endothelial cell responses in sepsis-induced acute kidney injury.

Molema G, Zijlstra J, van Meurs M, Kamps J Nat Rev Nephrol. 2021; 18(2):95-112.

PMID: 34667283 DOI: 10.1038/s41581-021-00489-1.

Blood-brain barrier dysfunction in ischemic stroke and diabetes: the underlying link, mechanisms and future possible therapeutic targets.

Wicha P, Das S, Mahakkanukrauh P Anat Cell Biol. 2021; 54(2):165-177.

PMID: 33658432 PMC: 8225477. DOI: 10.5115/acb.20.290.

References

Deutschman D, Carstens J, Klepper R, Smith W, Page M, Young T . Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J. 2003; 146(1):62-8. DOI: 10.1016/S0002-8703(03)00118-2. View

Jung B, Obinata H, Galvani S, Mendelson K, Ding B, Skoura A . Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development. Dev Cell. 2012; 23(3):600-10. PMC: 3443394. DOI: 10.1016/j.devcel.2012.07.015. View

Argraves K, Gazzolo P, Groh E, Wilkerson B, Matsuura B, Twal W . High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J Biol Chem. 2008; 283(36):25074-81. PMC: 2529014. DOI: 10.1074/jbc.M801214200. View

Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J . Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002; 296(5566):346-9. DOI: 10.1126/science.1070238. View

Wei Y, Yemisci M, Kim H, Yung L, Shin H, Hwang S . Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011; 69(1):119-29. PMC: 3200194. DOI: 10.1002/ana.22186. View

Feistritzer C, Riewald M . Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005; 105(8):3178-84. DOI: 10.1182/blood-2004-10-3985. View

Czech B, Pfeilschifter W, Mazaheri-Omrani N, Strobel M, Kahles T, Neumann-Haefelin T . The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun. 2009; 389(2):251-6. DOI: 10.1016/j.bbrc.2009.08.142. View

Pappu R, Schwab S, Cornelissen I, Pereira J, Regard J, Xu Y . Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007; 316(5822):295-8. DOI: 10.1126/science.1139221. View

Whetzel A, Bolick D, Srinivasan S, Macdonald T, Morris M, Ley K . Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ Res. 2006; 99(7):731-9. DOI: 10.1161/01.RES.0000244088.33375.52. View

10.

Keul P, Tolle M, Lucke S, von Wnuck Lipinski K, Heusch G, Schuchardt M . The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006; 27(3):607-13. DOI: 10.1161/01.ATV.0000254679.42583.88. View

11.

Ishii I, Ye X, Friedman B, Kawamura S, Contos J, Kingsbury M . Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. J Biol Chem. 2002; 277(28):25152-9. DOI: 10.1074/jbc.M200137200. View

12.

Ames 3rd A, Wright R, Kowada M, THURSTON J, Majno G . Cerebral ischemia. II. The no-reflow phenomenon. Am J Pathol. 1968; 52(2):437-53. PMC: 2013326. View

13.

Dudek S, Jacobson J, Chiang E, Birukov K, Wang P, Zhan X . Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J Biol Chem. 2004; 279(23):24692-700. DOI: 10.1074/jbc.M313969200. View

14.

Argraves K, Sethi A, Gazzolo P, Wilkerson B, Remaley A, Tybjaerg-Hansen A . S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 2011; 10:70. PMC: 3116499. DOI: 10.1186/1476-511X-10-70. View

15.

Venkataraman K, Lee Y, Michaud J, Thangada S, Ai Y, Bonkovsky H . Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res. 2008; 102(6):669-76. PMC: 2659392. DOI: 10.1161/CIRCRESAHA.107.165845. View

16.

Mizugishi K, Yamashita T, Olivera A, Miller G, Spiegel S, Proia R . Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol. 2005; 25(24):11113-21. PMC: 1316977. DOI: 10.1128/MCB.25.24.11113-11121.2005. View

17.

Poti F, Ceglarek U, Burkhardt R, Simoni M, Nofer J . SKI-II--a sphingosine kinase 1 inhibitor--exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet. Atherosclerosis. 2015; 240(1):212-5. DOI: 10.1016/j.atherosclerosis.2015.03.020. View

18.

Kim G, Yang L, Zhang G, Zhao H, Selim M, McCullough L . Critical role of sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental stroke. Nat Commun. 2015; 6:7893. PMC: 4587559. DOI: 10.1038/ncomms8893. View

19.

Klingenberg R, Nofer J, Rudling M, Bea F, Blessing E, Preusch M . Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2007; 27(11):2392-9. DOI: 10.1161/ATVBAHA.107.149476. View

20.

Takeya H, Gabazza E, Aoki S, Ueno H, Suzuki K . Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells. Blood. 2003; 102(5):1693-700. DOI: 10.1182/blood-2002-11-3607. View